Serum and urine interferon-inducible protein 10, galectin-9, and SIGLEC-1 as biomarkers of disease activity in systemic lupus erythematosus

Authors

Şafak MİRİOĞLU, Istanbul University Istanbul Faculty of Medicine: Istanbul Universitesi Istanbul Tip FakultesiFollow
Suzan ÇINAR, Department of Immunology, Aziz Sancar Institute of Experimental Medicine, İstanbul University, İstanbul, TurkiyeFollow
Ömer ULUDAĞ, Division of Rheumatology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, TurkiyeFollow
Erdem GÜREL, Division of Rheumatology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, TurkiyeFollow
Sibel VARELCİ, Division of Rheumatology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, TurkiyeFollow
Yasemin ÖZLÜK, Department of Pathology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, TurkiyeFollow
Işın KILIÇASLAN, Department of Pathology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, TurkiyeFollow
Yasemin YALÇINKAYA, Division of Rheumatology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, TurkiyeFollow
Halil YAZICI, Division of Nephrology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, TurkiyeFollow
Ahmet GÜL, Division of Rheumatology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, TurkiyeFollow
Murat İNANÇ, Division of Rheumatology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, TurkiyeFollow
Bahar ARTIM ESEN, Division of Rheumatology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, TurkiyeFollow

DOI

10.55730/1300-0144.5804

Abstract

Background/aim: In this prospective study, we aimed to investigate the association of serum (s) and urine (u) IP-10, galectin-9, and SIGLEC-1 with disease activity in patients with systemic lupus erythematosus (SLE).Materials and methods: Sixty-three patients with active SLE (31 renal, 32 extrarenal) were included. Thirty patients with inactive SLE (15 renal, 15 extrarenal), 17 with renal active AAV, and 32 healthy volunteers were selected as control groups. Serum and urine IP-10, galectin-9, and SIGLEC-1 were tested using ELISA.Results: Levels of sIP-10 (p = 0.046), uIP-10 (p < 0.001), sGalectin-9 (p = 0.03), and uSIGLEC-1 (p = 0.006) were significantly higher in active SLE group compared to the inactive SLE; however, no differences were detected in the comparison of uGalectin-9 (p = 0.18) and sSIGLEC-1 (p = 0.69) between two groups. None of the biomarkers discriminated patients with active renal SLE from active extrarenal SLE. ROC analyses revealed an AUC of 0.63 (0.52–0.73) for sIP-10, 0.78 (0.68–0.86) for uIP-10, 0.64 (0.53–0.74) for sGalectin-9, and 0.68 (0.57–0.77) for uSIGLEC-1 in discriminating disease activity in SLE, which did not outperform C3 (0.75, 0.64–0.84) and C4 (0.72, 0.61–0.82). sIP-10 (p = 0.001), uIP-10 (p = 0.042), and uGalectin-9 (p = 0.009) were significantly increased in patients with active renal SLE compared to active renal AAV. sGalectin-9 (p < 0.001) and sIP-10 levels (p = 0.06) were decreased after 8 (5–22.5) months of treatment.Conclusion: sIP-10, uIP-10, sGalectin-9, and uSIGLEC-1 reflect global disease activity in SLE but do not outperform C3 and C4. sIP-10 and uIP-10 may be specific for active SLE compared to active AAV. sIP-10 and sGalectin-9 might be valuable in monitoring response after treatment.

Keywords

biomarker, galectin-9, IP-10, SIGLEC-1, Systemic lupus erythematosus

First Page

391

Last Page

400

Recommended Citation

MİRİOĞLU, Şafak; ÇINAR, Suzan; ULUDAĞ, Ömer; GÜREL, Erdem; VARELCİ, Sibel; ÖZLÜK, Yasemin; KILIÇASLAN, Işın; YALÇINKAYA, Yasemin; YAZICI, Halil; GÜL, Ahmet; İNANÇ, Murat; and ARTIM ESEN, Bahar (2024) "Serum and urine interferon-inducible protein 10, galectin-9, and SIGLEC-1 as biomarkers of disease activity in systemic lupus erythematosus," Turkish Journal of Medical Sciences: Vol. 54: No. 2, Article 5. https://doi.org/10.55730/1300-0144.5804
Available at: https://journals.tubitak.gov.tr/medical/vol54/iss2/5